FDA Approves Tzield for Stage 3 Type 1 Diabetes Patients

The regulatory green light follows findings from the PROTECT study, which demonstrated that the drug effectively preserves beta cell function in newly diagnosed individuals. By intervening within eight weeks of a stage 3 diagnosis, clinicians can now offer a therapeutic option for patients whose bodies can no longer produce sufficient insulin. Tzield previously gained approval in 2022 for stage 2 patients, establishing it as the only disease-modifying treatment currently available for the autoimmune condition.

Breakthrough T1D CEO Aaron J. Kowalski described the decision as a milestone in diabetes care. While the current approval addresses a specific age bracket, ongoing research continues through Sanofi’s BETA-PRESERVE study to further evaluate long-term outcomes. This expansion also sets a regulatory precedent for future therapies utilizing C-peptide levels as a primary clinical trial endpoint, potentially accelerating the development of additional treatments for the 9.5 million people living with type 1 diabetes globally.